Sihuan Pharm Holdings Group Limited announced its interim business results for the six months ended June 30, 2024. During the period, the total income of the group was approximately RMB 949.7 million, a decrease of about 10.0% year-on-year. The income from medical beauty products increased by about 66.4% year-on-year to RMB 322.8 million, mainly due to the strategic cooperation and marketing strategy of the medical beauty platform Mu Yan Space. The income from generic pharmaceutical business decreased by about 29.4% to RMB 597.3 million, affected by the collection and inclusion of certain products in the key monitoring catalog. The income from innovative drugs and other pharmaceuticals increased by about 85.0% to RMB 29.6 million, as Xuanzhu Biotech's self-developed Class I innovative drug Annilazol sodium...Show More

Sihuan Pharm Holdings Group Limited announced its interim business results for the six months ended June 30, 2024. During the period, the total income of the group was approximately RMB 949.7 million, a decrease of about 10.0% year-on-year. The income from medical beauty products increased by about 66.4% year-on-year to RMB 322.8 million, mainly due to the strategic cooperation and marketing strategy of the medical beauty platform Mu Yan Space. The income from generic pharmaceutical business decreased by about 29.4% to RMB 597.3 million, affected by the collection and inclusion of certain products in the key monitoring catalog. The income from innovative drugs and other pharmaceuticals increased by about 85.0% to RMB 29.6 million, as Xuanzhu Biotech's self-developed Class I innovative drug Annilazol sodium was approved for marketing. The gross profit for the period was approximately RMB 608.5 million, a decrease of about 18.6% year-on-year. Research and development expenses decreased by 33.5% to RMB 195.6 million. The operating surplus was approximately RMB 109.1 million, a decrease of 25.4% year-on-year. The net loss for the period was approximately RMB 68.0 million, a decrease of 42.8% year-on-year. The net loss attributable to the company's owners was approximately RMB 33.4 million, a decrease of 32.7% year-on-year. The board of directors declared a mid-year cash dividend of RMB 1.9 per share.